Executive Management

Howard S. Jonas Chairman of the Board Howard S. Jonas has served as Chairman of the Board of Directors of the Company since August 17, 2017 and served as Chief Executive Officer from March 8, 2018 through April 30, 2021. Mr. Jonas has been a director of Rafael Pharmaceuticals since April 2013 and was appointed Chairman of the Board in April 2016. Mr. Jonas founded IDT in August 1990, and has served as Chairman of its Board of Directors since its inception. Mr. Jonas served as Chief Executive Officer of IDT from October 2009 through December 2013. Mr. Jonas has served as Chairman of the Board of Directors of Genie Energy Ltd. since January 2011, when it was spun off from IDT, and served as Chief Executive Officer of Genie from January 2014 until November 2017. Mr. Jonas served as the Chairman of the Board of Zedge, Inc., a former subsidiary of IDT that was spun off to stockholders in June 2016, from June 2016 to November 2016, and as the Vice Chairman of Zedge since November 2016. Mr. Jonas also serves as Chairman of the Board of IDW Media Holdings, Inc., a former subsidiary of IDT that was spun off to stockholders in September 2009 and served as Chief Executive officer until April 2020. Mr. Jonas is also the founder and has been President of Jonas Media Group (f/k/a Jonas Publishing) since its inception in 1979. Mr. Jonas received a B.A. in Economics from Harvard University. Ameet Mallik Chief Executive Officer Ameet Mallik has served as a director since June 2021 and the Company’s Chief Executive Officer since May 1, 2021. Mr. Mallik served as Executive Vice President and Head, U.S. Oncology of Novartis from November 2017 through April 2021. In this role, Mr. Mallik was responsible for Novartis’s commercial and medical oncology operations in the United States. From November 2015 to November 2017, Mr. Mallik served as Global Head, Marketing, Value and Access, and from April 2014 to November 2015 as Head, Latin America and Canada, both for Novartis Oncology. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Head of Biopharmaceuticals & Oncology Injectables at Sandoz. Mr. Mallik previously worked as an Associate Principal at McKinsey and Company. Mr. Mallik has been a member of the board of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) since August 2021. Mr. Mallik holds an M.B.A. from The Wharton School at the University of Pennsylvania, and an M.S. in Biotechnology and B.S. in Chemical Engineering, both from Northwestern University. Menachem Ash President and General Counsel Menachem Ash has served as the Company’s President since July 2017 and General Counsel since March 2018. He has served as Executive Vice President of Strategy and Legal Affairs of IDT since October 2012. Mr. Ash served as the managing attorney of IDT’s legal department from June 2011 to October 2012. Mr. Ash has served as senior counsel to several IDT divisions since he joined IDT in July 2004, including IDT Telecom and IDT Carmel. Prior to joining IDT, Mr. Ash served as General Counsel to Telstar International, Inc., a telecommunications services provider. Mr. Ash also worked at KPMG as a senior associate in its tax group focusing on financial services and technology companies. He is a graduate of Brooklyn College and the Benjamin N. Cardozo School of Law. Patrick Fabbio Chief Financial Officer Patrick Fabbio has served as Chief Financial Officer of the Company since September 2021. Mr. Fabbio has more than 25 years of financial, operational and transactional leadership experience in both publicly-traded and privately-held life science and pharmaceutical companies. Prior to joining Rafael Holdings, Mr. Fabbio was Chief Financial Officer of WindMIL Therapeutics Inc. Previously he served as the Chief Financial Officer of Progenics Pharmaceuticals, Inc., electroCore Medical, LLC; Vice President of Finance at NPS Pharmaceuticals, Inc.; Vice President of Finance, Innovation and Growth at Catalent Pharma Solutions Inc.; and Chief Financial Officer at Ikano Therapeutics. His other prior financial positions include roles at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. Mr. Fabbio is a board member of BeyondSpring Therapeutics, Inc. William 'Bill' Conkling Chief Commercial Officer William Conkling has served as Chief Commercial Officer of the Company since March 2021. Mr. Conkling has over 20 years’ experience in the pharmaceutical/biotech industry working in Oncology. He has extensive experience launching innovative oncology products. His experience spans all areas of commercialization including marketing, sales, market access, commercial operations and business development. Prior to joining the Company, Mr. Conkling helped lead the launch of Trodelvy at Immunomedics Inc. (acquired by Gilead for $21B in October 2020) as the VP Sales, Marketing and Market Access. Mr. Conkling also spent over 10 years at Novartis Oncology where he helped lead the launch of the first CAR-T therapy approved in the US as the Global Commercial Leader — Kymriah. Mr. Conkling earned his Bachelor’s Degree from Fordham University and his Master’s in Business Administration from New York University Stern School of Business in 1998.   Melissa Lozner Chief Compliance & Ethics Officer Melissa Lozner is a highly experienced legal and compliance leader with 20 years of diverse international and US experience in the health care industry and beyond. Prior to joining Rafael, Ms. Lozner served as Vice President, Head of Ethics, Risk & Compliance at Novartis, where she oversaw all aspects of the Ethics, Risk & Compliance department and program for the US Oncology business unit, and was a member of the US Oncology Country Leadership Team and Global Oncology Ethics, Risk & Compliance Leadership Team. Ms. Lozner joined Novartis in 2012, where she served as in-house counsel in roles of increasing responsibility supporting all aspects of the Global and US Oncology business units. Ms. Lozner began her career as a litigation attorney at the international law firm of Cravath, Swaine & Moore LLP. She then served as a Law Clerk to the Chief Judge Emeritus of the United States Court of Appeals for the Sixth Circuit. Following her clerkship, Ms. Lozner joined the law firm of Lowenstein Sandler, where she represented pharmaceutical and other clients in various matters including complex commercial litigation and white-collar criminal defense. While at Lowenstein, she helped to found the Lowenstein Center for the Public Interest and devoted a substantial portion of her practice to pro bono and public interest matters. Ms. Lozner holds a Bachelor of Science degree in Biology & Society from Cornell University, and a Juris Doctor degree from Boston University School of Law.     Brandi Robinson Chief Corporate Affairs Officer Brandi Robinson is responsible for the communications, government affairs and patient advocacy functions and is a member of the Rafael Holdings Executive Committee. Ms. Robinson is an accomplished communications executive that brings more than 20 years of experience in the pharmaceuticals, medical device and consumer health industries specializing in strategic communications, media relations, issues management, product communications, patient education campaigns, corporate reputation and internal communications. Most recently Ms. Robinson served as senior vice president and chief communications officer at Mallinckrodt Pharmaceuticals. Prior to that she led communications for Seattle Genetics as senior vice president, communications, Sanofi US as vice president and head of corporate communications, North America, and spent a number of years at Novartis Corporation in roles of increasing responsibility, including vice president and head of communications, North America. Ms. Robinson also held key roles at healthcare-focused public relations firms and nonprofit organizations. Ms. Robinson holds a bachelor’s degree from Fairleigh Dickinson University.